SCHEMBL20434656

SCHEMBL20434656

Cc1ccc2c(c1)[nH]c1c(C)c(OS(=O)(=O)c3cccc4c(N(C)C)cccc34)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 7/20 0.41
CA2 P00918 1/20 0.41
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
HIF1A Q16665 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
F2 P00734 2/20 0.37
PRSS1 P07477 2/20 0.37
PRSS2 P07478 2/20 0.37
PRSS3 P35030 2/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
HTR6 P50406 2/20 0.36
PARP14 Q460N5 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20434628 0.92 EDNRA (0.43) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL18488193 0.90 CA2 (0.39) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL689528 0.89 DYRK1A (0.42) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL12588733 0.88 MAOA (0.43) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL20434625 0.87 EDNRA (0.41) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL20434658 0.85 HTR6 (0.48) CA2F2KMT2AHTR6PARP14
SCHEMBL20434638 0.80 KIF11 (0.42) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL18487742 0.80 DYRK1A (0.41) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL18487738 0.77 DYRK1A (0.39) EDNRACA2CYP1A2CYP2C19HTT
SCHEMBL20434629 0.77 GAA (0.42) CYP1A2CYP2C19TDP1KMT2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180215712-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215712-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF AR, KLK3, BRDT EDNRA 338/4885CA2 1333/4885CYP1A2 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.